UNIVEST FINANCIAL Corp Lowers Position in Regeneron Pharmaceuticals, Inc. $REGN

UNIVEST FINANCIAL Corp lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,400 shares of the biopharmaceutical company’s stock after selling 923 shares during the quarter. Regeneron Pharmaceuticals makes up about 0.8% of UNIVEST FINANCIAL Corp’s holdings, making the stock its 27th largest position. UNIVEST FINANCIAL Corp’s holdings in Regeneron Pharmaceuticals were worth $14,974,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of REGN. Vanguard Group Inc. grew its stake in shares of Regeneron Pharmaceuticals by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock worth $7,004,838,000 after acquiring an additional 26,884 shares in the last quarter. Dodge & Cox lifted its position in shares of Regeneron Pharmaceuticals by 18.9% during the third quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock valued at $2,558,804,000 after purchasing an additional 724,562 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Regeneron Pharmaceuticals by 6.0% during the third quarter. Franklin Resources Inc. now owns 2,453,143 shares of the biopharmaceutical company’s stock valued at $1,379,329,000 after purchasing an additional 139,647 shares in the last quarter. Capital World Investors boosted its holdings in Regeneron Pharmaceuticals by 1.6% during the third quarter. Capital World Investors now owns 1,998,366 shares of the biopharmaceutical company’s stock worth $1,123,609,000 after purchasing an additional 32,348 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in Regeneron Pharmaceuticals by 38.0% during the third quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock worth $834,675,000 after purchasing an additional 408,649 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director owned 17,503 shares in the company, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jason Pitofsky sold 2,036 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares of the company’s stock, valued at $3,325,837.44. The trade was a 32.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,874 shares of company stock worth $3,013,262 over the last ninety days. 6.97% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have commented on REGN shares. Morgan Stanley increased their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Piper Sandler initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 31st. They issued an “overweight” rating and a $875.00 target price for the company. Oppenheimer reaffirmed an “outperform” rating and set a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $800.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, April 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $826.59.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $714.89 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $75.58 billion, a PE ratio of 17.42, a price-to-earnings-growth ratio of 1.60 and a beta of 0.30. The firm’s 50 day simple moving average is $752.68 and its 200 day simple moving average is $740.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating the consensus estimate of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same period last year, the firm earned $8.22 EPS. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.08 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be paid a dividend of $0.94 per share. The ex-dividend date of this dividend is Wednesday, May 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.16%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.